Tumor neoantigen is the truly foreign protein and entirely absent from normal human
organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors …

Antigen presentation by major histocompatibility complex class II (MHC-II) molecules is
crucial for eliciting an efficient immune response by CD4+ T cells and maintaining self …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …

Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and
control tumor growth. However, it remains difficult to predict the antigens that will be …

Background The human leucocyte antigen (HLA) complex controls adaptive immunity by
presenting defined fractions of the intracellular and extracellular protein content to immune …

Presentation of peptide antigens by MHC-II proteins is prerequisite to effective CD4 T cell
tolerance to self and to recognition of foreign antigens. Antigen uptake and processing …

In the last few years, advancement in the analysis of the MHC class II (MHC-II) ligandome in
several mouse and human haplotypes has increased our understanding of the molecular …

All nucleated mammalian cells express major histocompatibility complex (MHC) proteins
that present peptides on cell surfaces for immune surveillance. These MHC-presented …

Cancer immunotherapy has achieved multiple clinical benefits and has become an
indispensable component of cancer treatment. Targeting tumor-specific antigens, also …

Immunotherapy with neoantigens presented by major histocompatibility complex (MHC) is
one of the most promising approaches in cancer treatment. Using this approach, cancer …